Romanian National Registry of Outcomes After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis - RO-TAVI

Sponsor
Romanian Society of Cardiology (Other)
Overall Status
Recruiting
CT.gov ID
NCT04694859
Collaborator
(none)
500
1
30.8
16.3

Study Details

Study Description

Brief Summary

RO-TAVI is a national prospective, observational, multi-center registry registry of patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI) to assess patient care and outcomes.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcatheter Aortic Valve Implantation

Detailed Description

Background: Since the establishment of transcatheter aortic valve implantation (TAVI) in Romania in 2015 there has been a growing number of interventions being performed by an increasing number of hospitals throughout the country. In 2018, there were more than 250 implants, which are expected to grow in the following years by about 30% on an annual basis.

Objective: This is a national quality assurance initiative to improve patient care and outcomes. It further serves as a database for the assessment of the safety and efficacy of TAVI and its financial implications (e.g. reimbursement).

Design: National, prospective, observational, multi-center registry. All centers performing

TAVI in Romania; minimum cases per center for inclusion: 20 cases/year-to-date Population:

All patients undergoing TAVI in Romania at any of the participating centers with a CE-marked valve of any manufacturer given that they provide written informed consent.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Romanian National Registry of Outcomes After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis - RO-TAVI
Anticipated Study Start Date :
Jan 5, 2021
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Jul 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Symptomatic Severe Aortic Valve Stenosis

Patients >18 years old with symptomatic severe aortic valve stenosis.

Device: Transcatheter Aortic Valve Implantation
Transfemoral or transapical Transcatheter Aortic Valve Implantation

Outcome Measures

Primary Outcome Measures

  1. Mortality [1-year]

    All cause mortality

Secondary Outcome Measures

  1. Stroke [1-year]

    Ischemic or hemorrhagic cerebrovascular accident

  2. Bleeding [1-year]

    Major bleeding

  3. Myocardial ischemia [1-year]

    Acute myocardial infarction or recurrent angina

  4. Arrhythmia [1-year]

    Arrhythmias requiring permanent pacemaker implantation

  5. Vascular complications [1-year]

    Procedure related vascular complications

  6. Acute kidney injury [1-year]

    Procedure related renal dysfunction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • severe symptomatic aortic valve stenosis

  • high risk or patients deemed amenable for TAVI by a multidisciplinary team

  • signed informed consent to participate in the study

Exclusion Criteria:
  • inadequate annulus size (<18 mm, >29 mm)

  • left ventricle thrombus

  • active endocarditis

  • high risk of coronary ostium obstruction

  • plaques with mobile thrombi in the ascending aorta, or arch

  • hemodynamic instability

  • estimated life expectancy <1 year

  • comorbidity suggesting lack of improvement of quality of life

  • other situations adjudicated by the local HeartTeam

Contacts and Locations

Locations

Site City State Country Postal Code
1 Catalina A. Parasca, MD Bucuresti Romania 030423

Sponsors and Collaborators

  • Romanian Society of Cardiology

Investigators

  • Principal Investigator: Vlad A Iliescu, MD PhD, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
  • Principal Investigator: Bogdan A Popescu, MD PhD, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
  • Principal Investigator: Dragos Vinereanu, MD PhD, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Romanian Society of Cardiology
ClinicalTrials.gov Identifier:
NCT04694859
Other Study ID Numbers:
  • RO-TAVI
First Posted:
Jan 5, 2021
Last Update Posted:
Jan 5, 2021
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Romanian Society of Cardiology
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 5, 2021